Short description
Vaxart is a biotechnology company that develops vaccine technology for the treatment of infectious diseases.
Description
Vaxart is a clinical-stage company focused on developing oral recombinant protein vaccines based on its proprietary oral vaccine platform and direct-acting antivirals to treat infections that have limited therapeutic options. Vaxart’s oral vaccines are designed to generate broad and durable immune responses that protect against a wide range of infectious diseases and may be useful for the treatment of chronic viral infections and cancer. Vaxart’s oral vaccines are administered using a convenient room temperature-stable tablet, rather than by injection. Vaxart believes that tablet vaccines are easier to distribute and administer than injectable vaccines, and have the potential to significantly increase vaccination rates. Vaxart’s development programs include oral tablet vaccines that are designed to protect against norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV). Through the merger, Vaxart also acquired antiviral drug candidates, including teslexivir (BTA074), an antiviral treatment for condyloma caused by HPV types 6 and 11.
Last funding
No Way
Sign in for full access
Total funding
$$3123123
Sign in for full access
Location
San Francisco, California, United States, North America
Founded on
January 1, 2004
Exited on
February 14, 2018
Went public on
February 14, 2018
Stock symbol
VXRT
Non-profit?
No
Acquired?
No
Employees count
101-250
Revenue range
$7890 - 12340
Sign in for full access
Investors
Noaccessforu, Absolutely Noaccess, Uh Ohhhh, Uh Ohhhh, Cannot Access, Uh Ohhhh, Blurry Noaccess
Sign in for full access
Founders
Sean Tucker